Alumis' Oral Psoriasis Med Poised for Approval, Challenges Big Pharma in Major Markets

Alumis' oral psoriasis treatment has shown positive results in a pivotal trial, potentially leading to FDA approval and challenging big pharma in major markets. The stock has surged following the announcement. Alumis is a San Francisco-based biotech company that focuses on developing novel oral therapies for inflammatory diseases.